Left Menu
Development News Edition

Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk -study

"There is no doubt in my mind that this will be a major player" as an initial treatment for advanced kidney cancer, said lead researcher Dr. Toni Choueiri from Dana-Farber Cancer Institute in Boston. He noted that the oncology community is already familiar with both drugs and that the combination demonstrated positive results on all the study's goals.

Reuters | Updated: 19-09-2020 03:35 IST | Created: 19-09-2020 03:35 IST
Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk -study

Bristol Myers Squibb Co's cancer immunotherapy Opdivo in combination with Exelixis Inc's Cabometyx reduced the risk of death by 40% in previously untreated patients with advanced kidney cancer, according to data from a late-stage study to be presented on Saturday.

The drug combination also doubled patients' median length of time before their cancer began to worsen to 16.6 months compared to progression-free survival of 8.3 months for patients treated with the chemotherapy sunitinib, an older Pfizer Inc drug sold under the brand name Sutent. "There is no doubt in my mind that this will be a major player" as an initial treatment for advanced kidney cancer, said lead researcher Dr. Toni Choueiri from Dana-Farber Cancer Institute in Boston.

He noted that the oncology community is already familiar with both drugs and that the combination demonstrated positive results on all the study's goals. The Phase III study of 651 patients with advanced or metastatic renal cell carcinoma was being presented as part of the European Society for Medical Oncology meeting being held virtually this year. A brief summary of the data, known as an abstract, was released on Friday.

Researchers said the safety of the combination was manageable and consistent with the side effect profile of the two drugs when used individually. Opdivo is one of Bristol’s top-selling drugs, with analysts forecasting nearly $7 billion in sales this year.

The new data could help boost sales that have slowed in recent years as Opdivo was eclipsed by Merck & Co’s rival drug Keytruda.


TRENDING

OPINION / BLOG / INTERVIEW

New farm bills in India: Focusing on farms or farmers?

... ...

Kenya’s COVID-19 response: Chaos amid lack of information

Confusing numbers and scanty information on how effective curfews and lockdowns have been in breaking transmission have amplified coordination and planning challenges in Kenyas response to COVID-19. Without accurate data, it is impossible t...

Farkhad Akhmedov: Calculating the price of impunity from the law

In insistences such as the battle over the Luna, Akhmedov has resorted to extreme legal machinations to subvert the High Courts decision and keep his assets from being seized. ...

Guinea’s elections hearken back to the autocracy and violence of its past

... ...

Videos

Latest News

Influential US Senators welcome India inviting Australia to Malabar exercise

A bipartisan group of influential American Senators on Tuesday welcomed Indias decision to invite Australia for the annual Malabar naval exercise involving Japan and the United States. In a significant move that comes amid a Sino-India bord...

UN urges people to #PledgetoPause before sharing information online

Antnio Guterres will on Wednesday launch the PledgetoPause campaign as part of wider efforts to create what the UN hopes will be a new social media norm to help combat the impact of viral misinformation. The campaign is based on research ...

Documents in Ghislaine Maxwell criminal case expected to be released by Thursday

A U.S. judge on Tuesday ordered the release of a deposition that British socialite Ghislaine Maxwell gave in 2016 related to her dealings with the late financier Jeffrey Epstein, and which she had fought to keep under wraps.U.S. District Ju...

India remains on South Africa's updated list of high-risk COVID-19 countries, travel restrictions continue

South Africa has reviewed its list of high-risk COVID-19 countries, sharply reducing the number but maintaining travel restrictions on people visiting the country from India. In its updated list released on October 19, the Department of Hom...

Give Feedback